The effectiveness of bisphosphonate treatment for post-menopausal osteoporosis depends on patients adhering to the therapeutic regimen. We previously showed that patients prefer a oncemonthly regimen and the present followup study aimed to analyse patients' motivation for this preference. Women with post-menopausal osteoporosis (n = 2035) completed a questionnaire targeting their bisphosphonate treatment preferences. The majority had chosen the once-monthly regimen due to the comfort (69%) and simplicity (59%) of the treatment and the need to take fewer pills (55%). Friends, relatives and print media were highlighted as important sources of information and many patients indicated a need for more information about osteoporosis and its management. Gastrointestinal and muscular side-effects were reported by about one-third of the patients, but these were well tolerated. It is concluded that once-monthly bisphosphonate treatment was preferred due to improved quality of life and should be offered to all patients with postmenopausal osteoporosis.
Introduction
Bisphosphonates are the most effective currently available drugs for the treatment of post-menopausal osteoporosis, however recent evidence clearly shows that their benefit is strongly associated with therapeutic adherence. 1 Ibandronate was the first member of this group of drugs to be available as a monthly regimen. 2 Several studies, including the VIVA study, 3 have shown that a monthly regimen is very important for achieving good patient compliance, with the vast majority of patients preferring the once-monthly regimen. 4, 5 Poor compliance to osteoporosis treatment is related to several different factors, including the asymptomatic nature of the disease (if fractures are not present) and the gastrointestinal complications of bisphosphonate drugs. 6 Although it may seem obvious why patients choose low frequency regimens this has not yet been studied in detail according to the published literature. The aim of the present VIVA II questionnaire-based study was, therefore, to J Payer, DČierny, Z Killinger et al.
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analyse the reasons for preferring oncemonthly bisphosphonates in patients with post-menopausal osteoporosis as a follow-up to the published VIVA study. 3
Patients and methods

PATIENT RECRUITMENT
Patients in Slovakia who had voluntarily chosen a once-monthly regimen of taking bisphosphonates (rather than the onceweekly regimen) and had been on this for a variety of periods of time for the treatment of primary post-menopausal osteoporosis were recruited to the study by their attending physicians. Diagnosis of primary post-menopausal osteoporosis was on the basis of bone mineral density measurements. Signed informed consent was obtained from all study participants. The data were made anonymous before undergoing analysis.
QUESTIONNAIRE
The questionnaire, which comprised eight multiple choice questions, was filled out by patients during a visit to their physician's office between May and July 2008. Three of the questions were included in the analysis presented in this paper and one question was related to side effects; the other questions were patient-specific and, therefore, not suited to analysis. The three questions analysed asked how the patient had found about once-monthly treatment (excluding their physician), their reasons for preferring the once-monthly treatment, and what information related to osteoporosis they would like to receive.
Results
A total of 2035 questionnaires were completed over a period of 3 months by patients with a mean ± SD age of 64 ± 10.2 years. The mean ± SD duration of treatment with once-monthly bisphosphonates was 9 ± 3 months.
Information about the possibility of taking bisphosphonates once monthly is given to patients by physicians, but the questionnaire indicated that other sources of information are also important and these are shown in Fig. 1 . Interestingly, friends, relatives and print media were reported as sources of information more often than television, radio and the internet, despite frequent commercial coverage. Reasons for preferring the once-monthly regimen are shown in Fig. 2 . The three most popular reasons were the need to take fewer pills, convenience and simplicity of treatment. A smaller number of patients reported independence as an important factor and a minority of patients reported fewer reminders of the disease or the possibility of treatment continuation (better adherence and staying on the treatment longer) as reasons for preferring the oncemonthly regimen.
Many patients wanted to receive further information about osteoporosis (Fig. 3 ). There were no major differences between the need for general information, drug-specific information and information related to lifestyle (exercises and nutrition). 
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Gastrointestinal and muscular side-effects were reported by approximately one-third of the patients: symptoms of reflux were reported by 37%, other gastrointestinal symptoms by 28% and muscular side-effects by 32% of the patients. The side-effects were all very well tolerated and did not cause any discontinuation of treatment.
Discussion
This study indicated that the most important reasons for patients preferring the oncemonthly regimen of bisphosphonates relate to an improved lifestyle (convenience, simplicity, fewer pills). This result is probably specific to diseases with few or no symptoms, but highlights the complexity of managing osteoporosis, hypertension and similar diseases. In a study comparing compliance in seven different diseases, osteoporosis treatment had one of the lowest adherence rates, with only gout treatment having even worse results. 7 It is, therefore, important to analyse further the factors affecting adherence to osteoporosis therapy. A small, recently published study of compliance in osteoporosis treatment confirmed previous studies, but highlighted the variability in reasons for non-adherence. 8 Individual management of adherence to treatment is needed and requires substantial attention from physicians.
A once-a-year regimen of intravenous ibandronate is currently also available. Its safety and efficiency has been demonstrated in large clinical trials, 9 but the effects on treatment persistence are as yet unknown. As a new option for the patients and their attending physicians, it has the potential to improve outcomes in general practice. 10 An interesting outcome from the analysis of questionnaires in the present study is that friends and relatives of the patients are more important sources of information than television or the internet. In addition, patients wanted more information about osteoporosis and its management. This should be taken into account by physicians and pharmaceutical companies when communicating with patients.
Although in some countries there are still problems with changing from a daily regimen to a weekly regimen, 11 bisphosphonate treatment is clearly moving towards low-frequency administration. Further studies need to focus on the potential of the annual regimen of intravenous bisphosphonate treatment to improve adherence and the long-term outcome of osteoporosis therapy.
